

Lorelei A Mucci, Scd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3617295/publications.pdf>

Version: 2024-02-01

384
papers

21,957
citations

10389

72
h-index

13379

130
g-index

392
all docs

392
docs citations

392
times ranked

32930
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. <i>Lancet Public Health</i> , The, 2020, 5, e475-e483.	10.0	1,595
2	Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. <i>Cancer Discovery</i> , 2020, 10, 783-791.	9.4	1,286
3	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	21.4	652
4	Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 68.	7.4	648
5	SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. <i>Nature</i> , 2011, 470, 269-273.	27.8	462
6	The Epidemiology of Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030361.	6.2	461
7	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014, 46, 1103-1109.	21.4	408
8	Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. <i>Lancet Oncology</i> , The, 2008, 9, 1039-1047.	10.7	385
9	Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?. <i>Journal of Clinical Oncology</i> , 2009, 27, 3459-3464.	1.6	329
10	<i>TMPRSS2</i> and COVID-19: Serendipity or Opportunity for Intervention?. <i>Cancer Discovery</i> , 2020, 10, 779-782.	9.4	329
11	Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 519-532.	6.3	328
12	Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 815-825.	6.3	286
13	Telomere length predicts survival independent of genetic influences. <i>Aging Cell</i> , 2007, 6, 769-774.	6.7	271
14	The <i>TMPRSS2:ERG</i> Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1497-1509.	2.5	268
15	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	21.4	264
16	A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer. <i>PLoS Medicine</i> , 2007, 4, e103.	8.4	243
17	Health status and health care use of Massachusetts women reporting partner abuse. <i>American Journal of Preventive Medicine</i> , 2000, 19, 302-307.	3.0	241
18	ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 1109-1122.	8.2	227

#	ARTICLE	IF	CITATIONS
19	Vitamin D-Related Genetic Variation, Plasma Vitamin D, and Risk of Lethal Prostate Cancer: A Prospective Nested Case-Control Study. <i>Journal of the National Cancer Institute</i> , 2012, 104, 690-699.	6.3	196
20	Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. <i>Gastroenterology</i> , 2017, 153, 1284-1294.e1.	1.3	189
21	Dietary Lycopene, Angiogenesis, and Prostate Cancer: A Prospective Study in the Prostate-Specific Antigen Era. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt430-djt430.	6.3	174
22	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020, 38, 2798-2811.	1.6	170
23	The Heritability of Prostate Cancer in the Nordic Twin Study of Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2303-2310.	2.5	169
24	Fish consumption and prostate cancer risk: a review and meta-analysis. <i>American Journal of Clinical Nutrition</i> , 2010, 92, 1223-1233.	4.7	167
25	ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. <i>Genes and Development</i> , 2013, 27, 683-698.	5.9	163
26	Immediate Risk of Suicide and Cardiovascular Death After a Prostate Cancer Diagnosis: Cohort Study in the United States. <i>Journal of the National Cancer Institute</i> , 2010, 102, 307-314.	6.3	156
27	A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv346.	6.3	149
28	mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2391-2396.	1.6	140
29	The Mediterranean diet, plasma metabolome, and cardiovascular disease risk. <i>European Heart Journal</i> , 2020, 41, 2645-2656.	2.2	138
30	A 25-Year Prospective Study of Plasma Adiponectin and Leptin Concentrations and Prostate Cancer Risk and Survival. <i>Clinical Chemistry</i> , 2010, 56, 34-43.	3.2	137
31	Mediterranean dietary pattern and mortality among young women: a cohort study in Sweden. <i>British Journal of Nutrition</i> , 2006, 96, 384-392.	2.3	131
32	Circadian Disruption, Sleep Loss, and Prostate Cancer Risk: A Systematic Review of Epidemiologic Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1002-1011.	2.5	131
33	Vitamin D Receptor Protein Expression in Tumor Tissue and Prostate Cancer Progression. <i>Journal of Clinical Oncology</i> , 2011, 29, 2378-2385.	1.6	130
34	Coffee Consumption and Prostate Cancer Risk and Progression in the Health Professionals Follow-up Study. <i>Journal of the National Cancer Institute</i> , 2011, 103, 876-884.	6.3	127
35	Temporal Trends in Cause of Death Among Swedish and US Men with Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1335-1342.	6.3	126
36	Mounting Evidence for Prediagnostic Use of Statins in Reducing Risk of Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1-2.	1.6	126

#	ARTICLE	IF	CITATIONS
37	Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. <i>European Urology</i> , 2016, 70, 549-552.	1.9	121
38	Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 495.	7.1	118
39	Prospective Study of Prostate Tumor Angiogenesis and Cancer-Specific Mortality in the Health Professionals Follow-Up Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5627-5633.	1.6	117
40	Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of β -catenin in prostate cancer. <i>Laboratory Investigation</i> , 2008, 88, 1340-1348.	3.7	116
41	Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk, and Survival. <i>Journal of Clinical Oncology</i> , 2010, 28, 3958-3964.	1.6	113
42	A Large Multiethnic Genome-Wide Association Study of Prostate Cancer Identifies Novel Risk Variants and Substantial Ethnic Differences. <i>Cancer Discovery</i> , 2015, 5, 878-891.	9.4	111
43	Evaluation of the 8q24 Prostate Cancer Risk Locus and MYC Expression. <i>Cancer Research</i> , 2009, 69, 5568-5574.	0.9	110
44	Immunohistochemical Expression of BRCA1 and Lethal Prostate Cancer. <i>Cancer Research</i> , 2010, 70, 3136-3139.	0.9	110
45	Metformin Use and Prostate Cancer Risk. <i>European Urology</i> , 2014, 66, 1012-1020.	1.9	109
46	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. <i>Nature Communications</i> , 2019, 10, 4358.	12.8	109
47	The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. <i>Hepatology</i> , 2001, 34, 714-718.	7.3	105
48	Dietary acrylamide and risk of renal cell cancer. <i>International Journal of Cancer</i> , 2004, 109, 774-776.	5.1	105
49	Immediate Risk for Cardiovascular Events and Suicide Following a Prostate Cancer Diagnosis: Prospective Cohort Study. <i>PLoS Medicine</i> , 2009, 6, e1000197.	8.4	103
50	Pregnancy estriol, estradiol, progesterone and prolactin in relation to birth weight and other birth size variables (United States). <i>Cancer Causes and Control</i> , 2003, 14, 311-318.	1.8	101
51	Aneuploidy drives lethal progression in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11390-11395.	7.1	101
52	Lifestyle and dietary factors in the prevention of lethal prostate cancer. <i>Asian Journal of Andrology</i> , 2012, 14, 365-374.	1.6	100
53	Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2354-2363.	2.5	99
54	Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. <i>International Journal of Cancer</i> , 2009, 124, 2683-2689.	5.1	98

#	ARTICLE	IF	CITATIONS
55	Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 887-906.	2.5	98
56	Association of Prostate Cancer Risk Variants with Gene Expression in Normal and Tumor Tissue. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 255-260.	2.5	97
57	Cholesterol uptake and regulation in high-grade and lethal prostate cancers. <i>Carcinogenesis</i> , 2017, 38, 806-811.	2.8	93
58	Survivorship and Improving Quality of Life in Men with Prostate Cancer. <i>European Urology</i> , 2015, 68, 374-383.	1.9	91
59	Prospective study of dietary acrylamide and risk of colorectal cancer among women. <i>International Journal of Cancer</i> , 2006, 118, 169-173.	5.1	89
60	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	12.8	88
61	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	12.8	88
62	A Prospective Study on Dietary Acrylamide Intake and the Risk for Breast, Endometrial, and Ovarian Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2503-2515.	2.5	87
63	Racial Differences in Genomic Profiling of Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1083-1085.	27.0	87
64	Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers. <i>JAMA Network Open</i> , 2020, 3, e2030072.	5.9	87
65	An Exploration of Shared Genetic Risk Factors Between Periodontal Disease and Cancers: A Prospective Co-Twin Study. <i>American Journal of Epidemiology</i> , 2010, 171, 253-259.	3.4	86
66	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. <i>BMJ Open</i> , 2018, 8, e022899.	1.9	85
67	Acrylamide Intake through Diet and Human Cancer Risk. <i>Journal of Agricultural and Food Chemistry</i> , 2008, 56, 6013-6019.	5.2	82
68	Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis. <i>PLoS Genetics</i> , 2010, 6, e1001204.	3.5	82
69	Whole Milk Intake Is Associated with Prostate Cancer-Specific Mortality among U.S. Male Physicians. <i>Journal of Nutrition</i> , 2013, 143, 189-196.	2.9	82
70	The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies. <i>American Journal of Epidemiology</i> , 2019, 188, 991-1012.	3.4	81
71	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1881-1890.	6.3	80
72	The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 145-150.	2.5	80

#	ARTICLE	IF	CITATIONS
73	Prediagnostic Plasma Vitamin D Metabolites and Mortality among Patients with Prostate Cancer. <i>PLoS ONE</i> , 2011, 6, e18625.	2.5	80
74	A Large Prospective Study of <i>SEP15</i> Genetic Variation, Interaction with Plasma Selenium Levels, and Prostate Cancer Risk and Survival. <i>Cancer Prevention Research</i> , 2010, 3, 604-610.	1.5	79
75	Sleep Disruption Among Older Men and Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 872-879.	2.5	79
76	Benchmarks for Operative Outcomes of Robotic and Open Radical Prostatectomy: Results from the Health Professionals Follow-up Study. <i>European Urology</i> , 2015, 67, 432-438.	1.9	79
77	Sleep disruption, chronotype, shift work, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. <i>Cancer Causes and Control</i> , 2016, 27, 1361-1370.	1.8	79
78	Prostate Cancer Cell Telomere Length Variability and Stromal Cell Telomere Length as Prognostic Markers for Metastasis and Death. <i>Cancer Discovery</i> , 2013, 3, 1130-1141.	9.4	77
79	Familial Risk and Heritability of Colorectal Cancer in the Nordic Twin Study of Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1256-1264.	4.4	77
80	Significance of <i>BRCA2</i> and <i>RB1</i> Co-loss in Aggressive Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2020, 26, 2047-2064.	7.0	77
81	Gleason Grade Progression Is Uncommon. <i>Cancer Research</i> , 2013, 73, 5163-5168.	0.9	76
82	Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 173-183.	4.7	76
83	Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. <i>European Urology</i> , 2014, 65, 1069-1075.	1.9	75
84	Urinary Melatonin Levels, Sleep Disruption, and Risk of Prostate Cancer in Elderly Men. <i>European Urology</i> , 2015, 67, 191-194.	1.9	74
85	Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2705-2711.	1.6	74
86	Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. <i>European Urology</i> , 2016, 70, 974-982.	1.9	72
87	<i>SPINK1</i> Protein Expression and Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2014, 20, 4904-4911.	7.0	71
88	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2018, 199, 1417-1425.	0.4	70
89	Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration. <i>iScience</i> , 2018, 9, 451-460.	4.1	69
90	Inflammation, Focal Atrophic Lesions, and Prostatic Intraepithelial Neoplasia with Respect to Risk of Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2280-2287.	2.5	68

#	ARTICLE	IF	CITATIONS
91	Milk and Dairy Consumption among Men with Prostate Cancer and Risk of Metastases and Prostate Cancer Death. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 428-436.	2.5	68
92	Dietary Fatty Acid Intake and Prostate Cancer Survival in Orebro County, Sweden. <i>American Journal of Epidemiology</i> , 2012, 176, 240-252.	3.4	67
93	Elevated IL-8, TNF- α , and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival. <i>Prostate</i> , 2014, 74, 820-828.	2.3	66
94	Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 851-860.	4.7	65
95	Maternal smoking during pregnancy and risk of brain tumors in the offspring. A prospective study of 1.4 million Swedish births. <i>Cancer Causes and Control</i> , 2004, 15, 997-1005.	1.8	63
96	Milk Intake in Early Life and Risk of Advanced Prostate Cancer. <i>American Journal of Epidemiology</i> , 2012, 175, 144-153.	3.4	63
97	Shiftwork and Prostate-Specific Antigen in the National Health and Nutrition Examination Survey. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1292-1297.	6.3	63
98	Precision Prevention and Early Detection of Cancer: Fundamental Principles. <i>Cancer Discovery</i> , 2018, 8, 803-811.	9.4	62
99	Diet and Hepatocellular Carcinoma: A Case-Control Study in Greece. <i>Nutrition and Cancer</i> , 2000, 38, 6-12.	2.0	61
100	Cholesterol Metabolism and Prostate Cancer Lethality. <i>Cancer Research</i> , 2016, 76, 4785-4790.	0.9	61
101	Aberrant Cytoplasmic Expression of p63 and Prostate Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 595-600.	2.5	60
102	Coffee consumption and plasma biomarkers of metabolic and inflammatory pathways in US health professionals. <i>American Journal of Clinical Nutrition</i> , 2019, 109, 635-647.	4.7	59
103	Dietary Acrylamide Intake and Risk of Premenopausal Breast Cancer. <i>American Journal of Epidemiology</i> , 2009, 169, 954-961.	3.4	58
104	Prognostic Utility of a New mRNA Expression Signature of Gleason Score. <i>Clinical Cancer Research</i> , 2017, 23, 81-87.	7.0	58
105	Validity and Reliability of Self-Reported Total Energy Expenditure Using a Novel Instrument. <i>European Journal of Epidemiology</i> , 2006, 21, 227-236.	5.7	57
106	Dietary zinc and prostate cancer survival in a Swedish cohort. <i>American Journal of Clinical Nutrition</i> , 2011, 93, 586-593.	4.7	57
107	Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1374-1380.	2.5	57
108	Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1050-1058.	2.5	55

#	ARTICLE	IF	CITATIONS
109	Genetic variation in RNASEL associated with prostate cancer risk and progression. <i>Carcinogenesis</i> , 2010, 31, 1597-1603.	2.8	54
110	ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. <i>Journal of Clinical Investigation</i> , 2018, 128, 2979-2995.	8.2	53
111	Family History of Breast or Prostate Cancer and Prostate Cancer Risk. <i>Clinical Cancer Research</i> , 2018, 24, 5910-5917.	7.0	52
112	Nausea and Vomiting in Pregnancy in Relation to Prolactin, Estrogens, and Progesterone. <i>Obstetrics and Gynecology</i> , 2003, 101, 639-644.	2.4	51
113	Perineural Invasion and Risk of Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 719-726.	2.5	51
114	Acrylamide exposure measured by food frequency questionnaire and hemoglobin adduct levels and prostate cancer risk in the Cancer of the Prostate in Sweden Study. <i>International Journal of Cancer</i> , 2009, 124, 2384-2390.	5.1	50
115	Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2618-2627.	2.5	50
116	Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. <i>Cancer</i> , 2015, 121, 1949-1956.	4.1	50
117	Prognostic Determinants in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 429-437.	2.0	48
118	Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. <i>Carcinogenesis</i> , 2012, 33, 404-412.	2.8	48
119	Body size across the life course and prostate cancer in the Health Professionals Follow-up Study. <i>International Journal of Cancer</i> , 2016, 138, 853-865.	5.1	48
120	A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. <i>Human Molecular Genetics</i> , 2010, 19, 3089-3101.	2.9	47
121	Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality. <i>Clinical Cancer Research</i> , 2009, 15, 3223-3230.	7.0	46
122	Genome-wide Association Study of Prostate Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2869-2876.	2.5	46
123	Association of plant-based diet index with prostate cancer risk. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 662-670.	4.7	45
124	Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study. <i>European Urology</i> , 2017, 72, 821-827.	1.9	44
125	Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. <i>International Journal of Cancer</i> , 2017, 141, 933-944.	5.1	44
126	Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. <i>Molecular Cancer Research</i> , 2019, 17, 446-456.	3.4	44

#	ARTICLE	IF	CITATIONS
127	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018, 9, 4616.	12.8	43
128	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. <i>European Urology</i> , 2019, 75, 399-407.	1.9	43
129	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1984-1993.	2.5	41
130	Sleep Duration and Disruption and Prostate Cancer Risk: a 23-Year Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 302-308.	2.5	41
131	Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 616-625.	6.3	40
132	Dietary acrylamide and risk of prostate cancer. <i>International Journal of Cancer</i> , 2012, 131, 479-487.	5.1	39
133	Circadian clock genes and risk of fatal prostate cancer. <i>Cancer Causes and Control</i> , 2015, 26, 25-33.	1.8	39
134	Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 771-774.	6.3	39
135	Do Genetic Factors Explain the Association Between Poor Oral Health and Cardiovascular Disease? A Prospective Study Among Swedish Twins. <i>American Journal of Epidemiology</i> , 2009, 170, 615-621.	3.4	38
136	5 α -Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer. <i>JAMA Internal Medicine</i> , 2014, 174, 1301.	5.1	38
137	Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGESâ€Reykjavik study. <i>Cancer</i> , 2019, 125, 2877-2885.	4.1	37
138	Racial disparities in prostate cancer among black men: epidemiology and outcomes. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 397-402.	3.9	37
139	Consumption of Fish Products across the Lifespan and Prostate Cancer Risk. <i>PLoS ONE</i> , 2013, 8, e59799.	2.5	37
140	Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. <i>Carcinogenesis</i> , 2011, 32, 853-859.	2.8	36
141	Associations between Dietary Acrylamide Intake and Plasma Sex Hormone Levels. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2024-2036.	2.5	36
142	Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. <i>Journal of the National Cancer Institute</i> , 2021, 113, 727-734.	6.3	36
143	Insufficient Sleep and Risk of Prostate Cancer in a Large Swedish Cohort. <i>Sleep</i> , 2015, 38, 1405-1410.	1.1	35
144	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. <i>Carcinogenesis</i> , 2018, 39, 1431-1437.	2.8	35

#	ARTICLE	IF	CITATIONS
145	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1086-1093.	7.0	35
146	Plasma metabolite profiles related to plant-based diets and the risk of type 2 diabetes. <i>Diabetologia</i> , 2022, 65, 1119-1132.	6.3	35
147	Molecular differences in transition zone and peripheral zone prostate tumors. <i>Carcinogenesis</i> , 2015, 36, 632-638.	2.8	34
148	The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1283-1289.	2.5	34
149	Use of 5 α -reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. <i>BMJ</i> , The, 2013, 346, f3406-f3406.	6.0	34
150	Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. <i>Prostate</i> , 2014, 74, 225-234.	2.3	33
151	Mediterranean Diet Score and prostate cancer risk in a Swedish population-based case-control study. <i>Journal of Nutritional Science</i> , 2013, 2, e15.	1.9	32
152	Dairy intake in relation to prostate cancer survival. <i>International Journal of Cancer</i> , 2017, 140, 2060-2069.	5.1	32
153	CanWalk: a feasibility study with embedded randomised controlled trial pilot of a walking intervention for people with recurrent or metastatic cancer. <i>BMJ Open</i> , 2017, 7, e013719.	1.9	31
154	The association of diabetes with risk of prostate cancer defined by clinical and molecular features. <i>British Journal of Cancer</i> , 2020, 123, 657-665.	6.4	31
155	Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. <i>European Urology Oncology</i> , 2022, 5, 18-29.	5.4	31
156	Birthweight differences between USA and China and their relevance to breast cancer aetiology. <i>International Journal of Epidemiology</i> , 2003, 32, 193-198.	1.9	30
157	One-carbon metabolism-related nutrients and prostate cancer survival. <i>American Journal of Clinical Nutrition</i> , 2009, 90, 561-569.	4.7	30
158	Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2520-2527.	3.6	30
159	Alcohol intake, drinking patterns, and prostate cancer risk and mortality: a 30-year prospective cohort study of Finnish twins. <i>Cancer Causes and Control</i> , 2016, 27, 1049-1058.	1.8	30
160	Deletion of Interstitial Genes between <i>TMPRSS2</i> and <i>ERG</i> Promotes Prostate Cancer Progression. <i>Cancer Research</i> , 2016, 76, 1869-1881.	0.9	29
161	Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 448-458.	7.0	29
162	Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1499-1511.	1.6	29

#	ARTICLE	IF	CITATIONS
163	Dairy consumption, plasma metabolites, and risk of type 2 diabetes. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 163-174.	4.7	29
164	Impact of neighborhood socioeconomic status, income segregation, and greenness on blood biomarkers of inflammation. <i>Environment International</i> , 2022, 162, 107164.	10.0	29
165	Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG-Positive Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2027-2031.	2.5	28
166	Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia. <i>International Journal of Cancer</i> , 2017, 141, 1794-1802.	5.1	28
167	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. <i>Clinical Cancer Research</i> , 2022, 28, 318-326.	7.0	28
168	Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. <i>British Journal of Obstetrics and Gynaecology</i> , 2001, 108, 291-294.	0.9	27
169	Increasing Use of Radical Prostatectomy for Nonlethal Prostate Cancer in Sweden. <i>Clinical Cancer Research</i> , 2012, 18, 6742-6747.	7.0	27
170	Prediagnostic Circulating Sex Hormones Are Not Associated with Mortality for Men with Prostate Cancer. <i>European Urology</i> , 2014, 65, 683-689.	1.9	27
171	Snus use, smoking and survival among prostate cancer patients. <i>International Journal of Cancer</i> , 2016, 139, 2753-2759.	5.1	27
172	Lung cancer, genetic predisposition and smoking: the Nordic Twin Study of Cancer. <i>Thorax</i> , 2017, 72, 1021-1027.	5.6	27
173	Metabolomic Signatures of Long-term Coffee Consumption and Risk of Type 2 Diabetes in Women. <i>Diabetes Care</i> , 2020, 43, 2588-2596.	8.6	27
174	Computational Reconstruction of NF- κ B Pathway Interaction Mechanisms during Prostate Cancer. <i>PLoS Computational Biology</i> , 2016, 12, e1004820.	3.2	27
175	Test-retest reliability of colorectal testing questions on the Massachusetts Behavioral Risk Factor Surveillance System (BRFSS). <i>Preventive Medicine</i> , 2005, 41, 303-311.	3.4	26
176	The Plight of the Potato: Is Dietary Acrylamide a Risk Factor for Human Cancer?. <i>Journal of the National Cancer Institute</i> , 2009, 101, 618-621.	6.3	26
177	The <i>TMPRSS2:ERG</i> fusion and response to androgen deprivation therapy for prostate cancer. <i>Prostate</i> , 2015, 75, 897-906.	2.3	26
178	The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. <i>Cancer & Metabolism</i> , 2016, 4, 22.	5.0	26
179	Pineal Gland Volume Assessed by MRI and Its Correlation with 6-Sulfatoxymelatonin Levels among Older Men. <i>Journal of Biological Rhythms</i> , 2016, 31, 461-469.	2.6	26
180	A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. <i>European Urology</i> , 2019, 76, 33-40.	1.9	26

#	ARTICLE	IF	CITATIONS
181	Diet and Lifestyle in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 1-27.	1.6	26
182	Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. <i>Prostate</i> , 2013, 73, 700-705.	2.3	25
183	Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study. <i>Prostate</i> , 2015, 75, 1384-1393.	2.3	25
184	Tumor expression of adiponectin receptor 2 and lethal prostate cancer. <i>Carcinogenesis</i> , 2015, 36, 639-647.	2.8	25
185	Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 765-772.	7.0	25
186	Maternal smoking and childhood leukemia and lymphoma risk among 1,440,542 Swedish children. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1528-33.	2.5	25
187	Rye bread consumption in early life and reduced risk of advanced prostate cancer. <i>Cancer Causes and Control</i> , 2012, 23, 941-950.	1.8	24
188	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 83-93.	1.6	24
189	Season of diagnosis and prognosis in breast and prostate cancer. <i>Cancer Causes and Control</i> , 2009, 20, 663-670.	1.8	23
190	Alcohol influence on acrylamide to glycidamide metabolism assessed with hemoglobin-adducts and questionnaire data. <i>Food and Chemical Toxicology</i> , 2010, 48, 820-824.	3.6	23
191	Common Genetic Variation of the Calcium-Sensing Receptor and Lethal Prostate Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 118-126.	2.5	23
192	Association of Prostate Cancer Risk Variants with <i>TMPRSS2:ERG</i> Status: Evidence for Distinct Molecular Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 745-749.	2.5	23
193	A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer. <i>European Urology</i> , 2023, 83, 343-351.	1.9	23
194	Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. <i>Prostate</i> , 2012, 72, 209-216.	2.3	22
195	Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. <i>Cancer Causes and Control</i> , 2013, 24, 2143-2155.	1.8	22
196	Interrogation of <i>ERG</i> gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome. <i>BJU International</i> , 2014, 113, 309-319.	2.5	22
197	Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 374-381.	2.8	22
198	Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer. <i>European Urology</i> , 2021, 79, 405-412.	1.9	22

#	ARTICLE	IF	CITATIONS
199	Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2001, 108, 291-294.	2.3	21
200	Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. <i>Prostate</i> , 2016, 76, 691-699.	2.3	21
201	MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 201-207.	2.5	21
202	Cancer Incidence and Mortality in 260,000 Nordic Twins With 30,000 Prospective Cancers. <i>Twin Research and Human Genetics</i> , 2019, 22, 99-107.	0.6	21
203	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 208-216.	2.5	21
204	Association between <i>Trichomonas vaginalis</i> and prostate cancer mortality. <i>International Journal of Cancer</i> , 2019, 144, 2377-2380.	5.1	21
205	A Single Nucleotide Polymorphism in Inflammatory Gene <i>RNASEL</i> Predicts Outcome after Radiation Therapy for Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1612-1619.	7.0	20
206	Total antioxidant intake in relation to prostate cancer incidence in the Health Professionals Follow-up Study. <i>International Journal of Cancer</i> , 2014, 134, 1156-1165.	5.1	20
207	Physical Activity and Prostate Tumor Vessel Morphology: Data from the Health Professionals Follow-up Study. <i>Cancer Prevention Research</i> , 2015, 8, 962-967.	1.5	20
208	A Walking Intervention Among Men With Prostate Cancer: A Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1021-e1028.	1.9	20
209	Early Life Residence, Fish Consumption, and Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 346-354.	2.5	20
210	A prospective study of pregravid oral contraceptive use in relation to fetal growth. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2004, 111, 989-995.	2.3	19
211	Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1682-1688.	2.5	19
212	Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. <i>British Journal of Cancer</i> , 2016, 114, 939-944.	6.4	19
213	The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. <i>Prostate</i> , 2017, 77, 1303-1311.	2.3	19
214	Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. <i>Cancer Prevention Research</i> , 2016, 9, 933-941.	1.5	18
215	Height, Obesity, and the Risk of <i>TMPRSS2:ERG</i> -Defined Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 193-200.	2.5	18
216	Midlife metabolic factors and prostate cancer risk in later life. <i>International Journal of Cancer</i> , 2018, 142, 1166-1173.	5.1	18

#	ARTICLE	IF	CITATIONS
217	Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia. <i>International Journal of Cancer</i> , 2022, 151, 1033-1046.	5.1	18
218	Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. <i>International Journal of Cancer</i> , 2015, 137, 949-958.	5.1	17
219	Physical Activity from Early Adulthood and Risk of Prostate Cancer: A 24-Year Follow-Up Study among Icelandic Men. <i>Cancer Prevention Research</i> , 2015, 8, 905-911.	1.5	17
220	Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors. <i>Prostate</i> , 2018, 78, 1172-1180.	2.3	17
221	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 410-418.	3.9	17
222	The Role of Epidemiology in Understanding the Relationship between Dietary Acrylamide and Cancer Risk in Humans. , 2005, 561, 39-47.		16
223	Plasma Levels of Acid-Labile Subunit, Free Insulin-Like Growth Factor-I, and Prostate Cancer Risk: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 484-491.	2.5	16
224	Risk of Sex-Specific Cancers in Opposite-Sex and Same-Sex Twins in Denmark and Sweden. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1622-1628.	2.5	16
225	Total antioxidant intake and prostate cancer in the Cancer of the Prostate in Sweden (CAPS) study. A case control study. <i>BMC Cancer</i> , 2016, 16, 438.	2.6	16
226	Guideline-Based Physical Activity and Survival Among US Men With Nonmetastatic Prostate Cancer. <i>American Journal of Epidemiology</i> , 2019, 188, 579-586.	3.4	16
227	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 532-541.	3.9	16
228	Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2023, 52, 71-86.	1.9	16
229	Birth Order, Sibship Size, and Housing Density in Relation to Tooth Loss and Periodontal Disease: A Cohort Study among Swedish Twins. <i>American Journal of Epidemiology</i> , 2004, 159, 499-506.	3.4	15
230	When death appears best for the child with severe malignancy: a nationwide parental follow-up. <i>Palliative Medicine</i> , 2006, 20, 567-577.	3.1	15
231	Coffee and risk of prostate cancer incidence and mortality in the Cancer of the Prostate in Sweden Study. <i>Cancer Causes and Control</i> , 2013, 24, 1575-1581.	1.8	15
232	Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 1431-1440.	3.4	15
233	Common medications and prostate cancer mortality: a review. <i>World Journal of Urology</i> , 2017, 35, 875-882.	2.2	15
234	Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort. <i>Cancer Prevention Research</i> , 2018, 11, 621-628.	1.5	15

#	ARTICLE	IF	CITATIONS
235	Circulating inflammation markers and prostate cancer. <i>Prostate</i> , 2019, 79, 1338-1346.	2.3	15
236	Epigenomic analysis of 5-hydroxymethylcytosine (5hmC) reveals novel DNA methylation markers for lung cancers. <i>Neoplasia</i> , 2020, 22, 154-161.	5.3	15
237	Genetic variation across C-reactive protein and risk of prostate cancer. <i>Prostate</i> , 2014, 74, 1034-1042.	2.3	14
238	ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). <i>Prostate</i> , 2015, 75, 1677-1681.	2.3	14
239	Intratumoral Sterol-27-Hydroxylase (<i>CYP27A1</i>) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1052-1058.	2.5	14
240	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF1, IGF1H, IGFBP1, IGFBP2 and IGFBP3 in a pooled analysis of 16,024 men from 22 studies. <i>International Journal of Cancer</i> , 2019, 145, 3244-3256.	5.1	14
241	Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer. <i>International Journal of Cancer</i> , 2019, 144, 2401-2407.	5.1	14
242	Alcoholism and risk for endometrial cancer. <i>International Journal of Cancer</i> , 2001, 93, 299-301.	5.1	13
243	Dietary Acrylamide Intake and Risk of Renal Cell Carcinoma in Two Large Prospective Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 979-982.	2.5	13
244	Genetic ablation of <i>FASN</i> attenuates the invasive potential of prostate cancer driven by <i>Pten</i> loss. <i>Journal of Pathology</i> , 2021, 253, 292-303.	4.5	13
245	Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. <i>PLoS ONE</i> , 2020, 15, e0243928.	2.5	13
246	Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in <i>BRCA2</i> -altered Prostate Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1792-1806.	7.0	13
247	Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. <i>European Urology</i> , 2015, 68, 1076-1082.	1.9	12
248	A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study. <i>Metabolites</i> , 2020, 10, 99.	2.9	12
249	Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. <i>JCO Global Oncology</i> , 2021, 7, 495-505.	1.8	12
250	Risk factors for cholangiocarcinoma in a low risk Caucasian population. <i>International Journal of Public Health</i> , 2001, 46, 182-185.	2.6	11
251	Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells. <i>Cancer Prevention Research</i> , 2015, 8, 737-742.	1.5	11
252	Sniffing out significant p values: genome wide association study of asparagus anosmia. <i>BMJ, The</i> , 2016, 355, i6071.	6.0	11

#	ARTICLE	IF	CITATIONS
253	Circulating Antioxidant Levels and Risk of Prostate Cancer by <i>TMPRSS2:ERG</i> . <i>Prostate</i> , 2017, 77, 647-653.	2.3	11
254	Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. <i>Cancer</i> , 2017, 123, 4130-4138.	4.1	11
255	Identification of Plasma Lipid Metabolites Associated with Nut Consumption in US Men and Women. <i>Journal of Nutrition</i> , 2019, 149, 1215-1221.	2.9	11
256	The Nordic Twin Study on Cancer – NorTwinCan. <i>Twin Research and Human Genetics</i> , 2019, 22, 817-823.	0.6	11
257	A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 2047-2054.	2.5	11
258	Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study. <i>European Urology Oncology</i> , 2019, 2, 126-134.	5.4	11
259	Low Expression of the Androgen-Induced Tumor Suppressor Gene <i>PLZF</i> and Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 707-714.	2.5	11
260	Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21). <i>Cancers</i> , 2021, 13, 4690.	3.7	11
261	Vitamin D and Prostate Cancer Risk—A Less Sunny Outlook?. <i>Journal of the National Cancer Institute</i> , 2008, 100, 759-761.	6.3	10
262	Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. <i>BJU International</i> , 2016, 118, 919-926.	2.5	10
263	Relation between tobacco control policies and population at high risk of lung cancer in the European Union. <i>Environmental Research</i> , 2019, 179, 108594.	7.5	10
264	Validity of Self-reported Health Plan Information in a Population-based Health Survey. <i>Journal of Public Health Management and Practice</i> , 2006, 12, 570-577.	1.4	9
265	Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. <i>International Journal of Cancer</i> , 2009, 125, 1143-1146.	5.1	9
266	<i>Methylcronyl-CoA</i> racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study. <i>Prostate</i> , 2012, 72, 301-306.	2.3	9
267	No Association of <i>ApoE</i> Genotype with Risk of Prostate Cancer: A Nested Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1632-1634.	2.5	9
268	Metabolic Factors and Prostate Cancer Risk. <i>Clinical Chemistry</i> , 2019, 65, 42-44.	3.2	9
269	Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL) <i>Tj ETQq1 1 0.784314 rgBT /Over</i> <i>Oncology</i> , 2016, 34, TPS5092-TPS5092.	1.6	9
270	A randomized trial of exercise on quality of life in men with metastatic prostate cancer: The ExPeCT Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-97.	1.6	9

#	ARTICLE	IF	CITATIONS
271	Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. <i>Prostate</i> , 2015, 75, 1926-1933.	2.3	8
272	GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 370-377.e1.	1.9	8
273	Smoking cessation among men following cancer diagnosis: a matched cohort study. <i>Journal of Cancer Survivorship</i> , 2018, 12, 786-793.	2.9	8
274	Pre-diagnostic 25-hydroxyvitamin D levels and survival in cancer patients. <i>Cancer Causes and Control</i> , 2019, 30, 333-342.	1.8	8
275	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 584-590.	2.5	8
276	Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell Level PI3K Pathway Activation. <i>Clinical Cancer Research</i> , 2020, 26, 5903-5913.	7.0	8
277	Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial. <i>Prostate</i> , 2020, 80, 1304-1313.	2.3	8
278	Association of nut consumption with risk of total cancer and 5 specific cancers: evidence from 3 large prospective cohort studies. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 1925-1935.	4.7	8
279	Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. <i>Molecular Oncology</i> , 2022, 16, 2451-2469.	4.6	8
280	Homogeneous Prostate Cancer Mortality in the Nordic Countries Over Four Decades. <i>European Urology</i> , 2010, 58, 427-432.	1.9	7
281	Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer. <i>Cancer Causes and Control</i> , 2015, 26, 1751-1759.	1.8	7
282	Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. <i>Carcinogenesis</i> , 2016, 37, 262-268.	2.8	7
283	Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of US Health Professionals. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	7
284	Validity and Relative Validity of Alternative Methods of Assessing Physical Activity in Epidemiologic Studies: Findings From the Men's Lifestyle Validation Study. <i>American Journal of Epidemiology</i> , 2022, 191, 1307-1322.	3.4	7
285	The Impact of PIK3R1 Mutations and Insulin PI3K Glycolytic Pathway Regulation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3603-3617.	7.0	7
286	Are there age-dependent effects of diet on prostate cancer risk?. <i>International Journal of Public Health</i> , 2001, 46, 329-334.	2.6	6
287	Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. <i>Cancer Causes and Control</i> , 2012, 23, 1359-1366.	1.8	6
288	The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies. <i>Cancer</i> , 2017, 123, 1490-1496.	4.1	6

#	ARTICLE	IF	CITATIONS
289	Expression and Genetic Variation in Neuroendocrine Signaling Pathways in Lethal and Nonlethal Prostate Cancer among Men Diagnosed with Localized Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1781-1787.	2.5	6
290	The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 456.	1.6	6
291	Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, 3272-3274.	1.6	6
292	Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival. <i>Prostate</i> , 2019, 79, 73-80.	2.3	6
293	Influence of KRAS mutations, persistent organic pollutants, and trace elements on survival from pancreatic ductal adenocarcinoma. <i>Environmental Research</i> , 2020, 190, 109781.	7.5	6
294	Insomnia among elderly men and risk of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 78-78.	1.6	6
295	Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, pkab091.	2.9	6
296	Racial Disparities in Prostate Cancer: Evaluation of Diet, Lifestyle, Family History, and Screening Patterns. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 982-990.	2.5	6
297	Support for Condom Availability and Needle Exchange Programs Among Massachusetts Adults, 1997. <i>AIDS Education and Prevention</i> , 2001, 13, 365-376.	1.1	5
298	Identifying Health Maintenance Organization Membership Through Self-report of Health Plan Name. <i>Journal of Public Health Management and Practice</i> , 2006, 12, 278-287.	1.4	5
299	The Nordic Nutrition Recommendations and prostate cancer risk in the Cancer of the Prostate in Sweden (CAPS) study. <i>Public Health Nutrition</i> , 2012, 15, 1897-1908.	2.2	5
300	Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. <i>Cancer Causes and Control</i> , 2016, 27, 1043-1047.	1.8	5
301	Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. <i>Prostate</i> , 2018, 78, 233-238.	2.3	5
302	Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency. <i>European Urology</i> , 2018, 74, 545-548.	1.9	5
303	Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. <i>European Urology</i> , 2020, 78, 637-639.	1.9	5
304	Baldness and Risk of Prostate Cancer in the Health Professionals Follow-up Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1229-1236.	2.5	5
305	Posttraumatic stress disorder and suicide among veterans with prostate cancer. <i>Psycho-Oncology</i> , 2021, 30, 581-590.	2.3	5
306	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 683-693.	2.3	5

#	ARTICLE	IF	CITATIONS
307	DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men. <i>JNCI Cancer Spectrum</i> , 2022, 6, pkab097.	2.9	5
308	Risk Assessment Criteria Applied to a Screening Exam: Implications for Improving the Efficiency of a Sealant Program. <i>Journal of Public Health Dentistry</i> , 2005, 65, 203-208.	1.2	4
309	Birth spacing and maternal risk of invasive epithelial ovarian cancer in a Swedish nationwide cohort. <i>Cancer Causes and Control</i> , 2008, 19, 1131-1137.	1.8	4
310	RE: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju018-dju018.	6.3	4
311	Single-nucleotide polymorphisms in DNMT3B gene and DNMT3B mRNA expression in association with prostate cancer mortality. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 284-291.	3.9	4
312	Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 32-37.	1.9	4
313	Aspirin use and prostate tumor angiogenesis. <i>Cancer Causes and Control</i> , 2022, 33, 149-151.	1.8	4
314	Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness.. <i>Journal of Clinical Oncology</i> , 2020, 38, 347-347.	1.6	4
315	Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 320-326.	3.9	4
316	Longitudinal trajectories of lifetime body shape and prostate cancer angiogenesis. <i>European Journal of Epidemiology</i> , 2022, 37, 261-270.	5.7	4
317	Diagnostic tests in urology: magnetic resonance imaging (<sc>MRI</sc>) for the staging of prostate cancer. <i>BJU International</i> , 2013, 111, 514-517.	2.5	3
318	Persistence of Trichomonas vaginalis serostatus in men over time. <i>Cancer Causes and Control</i> , 2015, 26, 1461-1466.	1.8	3
319	Regular aspirin use and gene expression profiles in prostate cancer patients. <i>Cancer Causes and Control</i> , 2018, 29, 775-784.	1.8	3
320	Family history of prostate cancer and the incidence of ERG– and phosphatase and tensin homolog–defined prostate cancer. <i>International Journal of Cancer</i> , 2020, 146, 2694-2702.	5.1	3
321	Exploratory assessment of pineal gland volume, composition, and urinary 6–sulfatoxymelatonin levels on prostate cancer risk. <i>Prostate</i> , 2021, 81, 487-496.	2.3	3
322	5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , .	2.5	3
323	p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up. <i>European Urology Oncology</i> , 2023, 6, 110-112.	5.4	3
324	Hospitalization for osteoarthritis and prostate cancer specific mortality among Swedish men with prostate cancer. <i>Cancer Epidemiology</i> , 2010, 34, 644-647.	1.9	2

#	ARTICLE	IF	CITATIONS
325	A Prospective Study of Aspirin Use and Prostate Cancer Risk by <i>TMPRSS2:ERG</i> Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1231-1233.	2.5	2
326	Is Vasectomy a Cause of Prostate Cancer?. <i>Journal of the National Cancer Institute</i> , 2020, 112, 5-6.	6.3	2
327	Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1000-1008.	2.5	2
328	Prenatal and Perinatal Factors and Risk of Cancer in Middle and Older Adulthood among Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1841-1845.	2.5	2
329	The effect of a structured exercise intervention on CTCs and platelet cloaking in patients with metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 243-243.	1.6	2
330	First look at patient reported outcomes from IRONMAN, the international registry of men with advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 69-69.	1.6	2
331	Is active surveillance safe for obese patients?. <i>Nature Reviews Urology</i> , 2014, 11, 489-490.	3.8	1
332	CanWalk: study protocol for a randomized feasibility trial of a walking intervention for people with recurrent or metastatic cancer. <i>Pilot and Feasibility Studies</i> , 2015, 1, 7.	1.2	1
333	Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. <i>Eur Urol</i> 2017;71:907-12. <i>European Urology</i> , 2017, 72, e9-e10.	1.9	1
334	Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 783-789.	2.5	1
335	Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. <i>Carcinogenesis</i> , 2020, 41, 904-908.	2.8	1
336	Can there be consensus on whether vasectomy is a prostate cancer risk factor?. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 939-941.	3.9	1
337	Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 751-756.	2.5	1
338	ABO blood group and risk of lethal prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 69-69.	1.6	1
339	Cholesterol metabolism and prostate cancer-specific mortality.. <i>Journal of Clinical Oncology</i> , 2015, 33, 12-12.	1.6	1
340	The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 196-196.	1.6	1
341	Increased cholesterol synthesis via squalene monooxygenase to predict lethal prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 77-77.	1.6	1
342	Association of loss of tumor suppressor ZFP36 with lethal prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5062-5062.	1.6	1

#	ARTICLE	IF	CITATIONS
343	IRONMAN: The international registry for men with advanced prostate cancer.. Journal of Clinical Oncology, 2022, 40, TPS190-TPS190.	1.6	1
344	Urinary 6-sulfatoxymelatonin Levels and Prostate Cancer Risk among Men in the Multiethnic Cohort. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 688-691.	2.5	1
345	COVID-19 and cancer in the United States. Epidemiologia E Prevenzione, 2020, 44, 26-27.	1.1	1
346	Dimitrios Trichopoulos: In Memoriam (1938â€“2014). Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 483-483.	2.5	0
347	Reply to D.C. Sokal et al. Journal of Clinical Oncology, 2015, 33, 670-671.	1.6	0
348	Reply to Herney Andr�s Garc�a-Perdomo and Ramiro Manzano Nunez's Letter to the Editor Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974â€“82. European Urology, 2016, 70, e156-e157.	1.9	0
349	CHALLENGE Trial 1 Year Feasibility Resultsâ€”Letter. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1277-1277.	2.5	0
350	Prostate cancer incidence as an iceberg. European Journal of Epidemiology, 2017, 32, 477-479.	5.7	0
351	Reply to C�dric Annweiler, Pierre Bigot, and Spyridon N. Karras� Letter to the Editor re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974â€“82. European Urology, 2017, 71, e18.	1.9	0
352	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 298-299.	4.4	0
353	Prostate Cancer National Summit�s Call to Action. Clinical Genitourinary Cancer, 2019, 17, 161-168.	1.9	0
354	Concerning trends in colorectal cancer in the wake of Chadwick Boseman�s death. Journal of Cancer Policy, 2020, 26, 100260.	1.4	0
355	Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer.. Journal of Clinical Oncology, 2021, 39, 250-250.	1.6	0
356	Racial differences in aneuploidy in high-grade muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2021, 39, 400-400.	1.6	0
357	Abstract 979: Bcl-2 inhibitor enhances anti-androgen therapy induced regression of castration sensitive prostate cancer. , 2021, , .		0
358	Abstract 2498: Identification and characterization of thePIK3R1-mutant subtype in PI3K-addicted prostate cancer. , 2021, , .		0
359	Abstract 863: Circadian gene expression in metastatic sites and association with survival in metastatic castration-resistant prostate cancer. , 2021, , .		0
360	Rye bread consumption in early life and reduced risk of advanced prostate cancer.. Journal of Clinical Oncology, 2012, 30, 79-79.	1.6	0

#	ARTICLE	IF	CITATIONS
361	Association of metabolic syndrome with poorer prostate cancer and overall survival in men receiving androgen deprivation therapy (ADT) for biochemical relapse.. Journal of Clinical Oncology, 2012, 30, 4555-4555.	1.6	0
362	Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer.. Journal of Clinical Oncology, 2013, 31, 2-2.	1.6	0
363	Ejaculation frequency and prostate cancer: A large, prospective study with 16 years of follow-up.. Journal of Clinical Oncology, 2013, 31, 5078-5078.	1.6	0
364	Vasectomy and risk of lethal prostate cancer: A 24-year prospective study.. Journal of Clinical Oncology, 2013, 31, 5086-5086.	1.6	0
365	Circadian dysrhythm and advanced prostate cancer.. Journal of Clinical Oncology, 2014, 32, 199-199.	1.6	0
366	Familial risk and heritability of genitourinary cancers in the Nordic Twin Cohorts.. Journal of Clinical Oncology, 2015, 33, 11-11.	1.6	0
367	Discovery and validation of a 30-gene expression signature to identify prostate cancer patients who are candidates for active surveillance.. Journal of Clinical Oncology, 2015, 33, 10-10.	1.6	0
368	Statin use at the time of initiation of androgen deprivation therapy (ADT) and time to progression (TTP) in patients with hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2015, 33, 148-148.	1.6	0
369	Regular aspirin use and the risk of lethal prostate cancer in the Physicians' Health Study.. Journal of Clinical Oncology, 2016, 34, 306-306.	1.6	0
370	Precision prevention of <i>TPR</i> SS2:ERG prostate cancer.. Journal of Clinical Oncology, 2016, 34, 78-78.	1.6	0
371	Differential gene expression in prostate tissue according to vasectomy.. Journal of Clinical Oncology, 2016, 34, 298-298.	1.6	0
372	Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by <i>TPR</i> SS2:ERG status.. Journal of Clinical Oncology, 2016, 34, 93-93.	1.6	0
373	Gene expression in prostate tissue according to frequency of ejaculation.. Journal of Clinical Oncology, 2016, 34, 25-25.	1.6	0
374	Expression and genetic variants in stress-related signaling pathways in lethal and nonlethal prostate cancer.. Journal of Clinical Oncology, 2016, 34, 5032-5032.	1.6	0
375	Long-term aspirin use and intratumoral gene expression in prostate cancer.. Journal of Clinical Oncology, 2017, 35, 106-106.	1.6	0
376	Dietary acrylamide intake and risk of renal cell carcinoma in two large prospective cohorts.. Journal of Clinical Oncology, 2018, 36, 677-677.	1.6	0
377	Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in prostate cancer.. Journal of Clinical Oncology, 2018, 36, 240-240.	1.6	0
378	Regulation of the tumor suppressor PLZF and prostate cancer prognosis.. Journal of Clinical Oncology, 2018, 36, 137-137.	1.6	0

#	ARTICLE	IF	CITATIONS
379	Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression.. Journal of Clinical Oncology, 2018, 36, 5044-5044.	1.6	0
380	Methylation-associated miR193b silencing activates master drivers of aggressive prostate cancer.. Journal of Clinical Oncology, 2019, 37, 240-240.	1.6	0
381	Long-term cancer survival in cohorts of U.S. health professionals.. Journal of Clinical Oncology, 2020, 38, 12075-12075.	1.6	0
382	5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health care.. Journal of Clinical Oncology, 2020, 38, 39-39.	1.6	0
383	Tumor protein expression of BRCA1 and development of lethal prostate cancer.. Journal of Clinical Oncology, 2020, 38, 65-65.	1.6	0
384	Is Epidemiology Implicating Extremely Low Frequency Electric and Magnetic Fields in Childhood Leukemia?. Environmental Health and Preventive Medicine, 2002, 7, 33-39.	3.4	0